XNK Therapeutics, founded in 2012, is one of the pioneering companies within the landscape of cell therapy. XNK Therapeutics focuses on cancer treatment by developing novel autologous NK cell-based therapies. This effort is strongly supported by the founding shareholders holding expertise in the field.

The shareholders have been actively engaged in the company, each contributing with their unique competence. This has led to a company culture built on active engagement and participation with the company’s and patients’ best interests at heart. XNK Therapeutics has actively been participating in public-private partnerships to develop its technology platform. To date, the main collaborating academic partners have been Karolinska Institutet and the Royal Institute of Technology, both in Stockholm, Sweden.